Anti-Cancer Drug Teysuno® has been launched in the United Kingdom.

The Company's Official Page
http://www.taiho.co.jp/english/news/20120411_2.html
Back To Previous Page

News Release

April 11, 2012
Taiho Pharmaceutical Co., Ltd.

Anti-Cancer Drug Teysuno® has been launched in the United Kingdom.

Tokyo, April 10, 2012,Taiho Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Masayuki Kobayashi) announced that our partner in Europe, Nordic Group BV (Head office: Hoofddorp, the Netherlands ; CEO and Managing Director: Drs. Hans Schram) has just started marketing of Teysuno® , which has been developed by Taiho Pharmaceutical Co., Ltd., in the United Kingdom following its launches in Sweden, Denmark, Norway and Finland, and will be progressively introduced in the other European Union countries before the end of the year.

Teysuno®, a novel oral anti-cancer agent, received Marketing Authorization from the EMA for the treatment of adults with advanced gastric cancer when given in combination with cisplatin (March 14, 2011)


Latest News: Pharmaceuticals

    この内容でのリリース掲載はまだ無いか、集計されておりません。

    この内容でのリリース掲載はまだ無いか、集計されておりません。

Most Popular: Pharmaceuticals

1. FDA ACCEPTS FOR REVIEW EISAI'S NDA ...
Eisai Co., Ltd. 2010/06/03
2. Taiho Pharmaceutical and Toray Industrie...
Taiho Pharmaceutical Co., Ltd. 2009/03/11
3. EISAI RECIEVES APPROVAL TO MARKET BOTULI...
Eisai Co., Ltd. 2011/01/21
4. Notice concerning the decision of matter...
Hisamitsu Pharmaceutical Co., Inc. 2009/02/26
5. Press Release relating to FDA Approval f...
Hisamitsu Pharmaceutical Co., Inc. 2008/02/22

Latest News: Taiho Pharmaceutical Co., Ltd.


Most Popular: Taiho Pharmaceutical Co., Ltd.

1. Taiho Pharmaceutical and Toray Industrie...
2009/03/11

Categories

Go to Page Top

View: Smartphone | PC

Language: English | Japanese

Home

Terms & Conditions

TwitterFacebook

About Us